GI Innovation is a South Korean bio-venture company, integrating basic science and translational innovation in developing biologics for patients around the world. GI Innovation’s strategic focus is on immuno-oncology and inflammation/immunology diseases. GI Innovation has established GI-SMART platform technology that is designed to accelerate the development of biologics through the efficient optimization of multi-targeting fusion protein therapeutics with high quality and high productivity.
We're tracking GI INNOVATION's market expansion
How GI INNOVATION's international expansion compares to its competitors
GI INNOVATIONYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 GI INNOVATIONYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
GI Innovation and GI Biome selected as semi-finalists in XPRIZE Healthspan competition, proposing anti-aging therapy combining GI-102 and GIB-7.
GI Innovation and GI Biome reach XPRIZE Healthspan semi-finals, proposing anti-aging therapy combining GI-102 and GIB-7. They're among 40 semi-finalists from 600 teams globally.
Three Korean biotech companies—Byegencell, GI Innovation, and Lunit—will present cancer therapy research at ASCO 2025, showcasing cell therapy, immunotherapy, and AI-based treatment platforms with promising clinical results.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about GI INNOVATION's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
